These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36303832)

  • 1. A systemic review of taxanes and their side effects in metastatic breast cancer.
    Lai JI; Chao TC; Liu CY; Huang CC; Tseng LM
    Front Oncol; 2022; 12():940239. PubMed ID: 36303832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2016 Apr; 16(2):73-81. PubMed ID: 26603443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
    Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taxane-containing regimens for metastatic breast cancer.
    Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit risk assessment and update on the use of docetaxel in the management of breast cancer.
    Alken S; Kelly CM
    Cancer Manag Res; 2013 Oct; 5():357-65. PubMed ID: 24143122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis.
    Liu M; Liu S; Yang L; Wang S
    BMC Cancer; 2021 Feb; 21(1):118. PubMed ID: 33541289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis.
    Lei L; Chen R; Fan L; Zheng W; Wang X
    Ann Palliat Med; 2022 Jul; 11(7):2382-2394. PubMed ID: 35927773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of taxanes in the treatment of breast cancer.
    Capri G; Tarenzi E; Fulfaro F; Gianni L
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):68-75. PubMed ID: 8614849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis.
    Lin YC; Chang HK; Chen JS; Wang HM; Yang TS; Liaw CC
    Jpn J Clin Oncol; 2007 Jan; 37(1):23-9. PubMed ID: 17172351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials.
    Liu Y; Ye G; Yan D; Zhang L; Fan F; Feng J
    Oncotarget; 2017 Sep; 8(42):72950-72958. PubMed ID: 29069839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
    Curr Med Res Opin; 2013 Feb; 29(2):117-25. PubMed ID: 23216340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and use of epirubicin-based therapy in the adjuvant setting.
    Mouridsen HT
    Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S34-40. PubMed ID: 11970748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of Taxane-Containing Regimens for Treatment of HER2-Negative Metastatic Breast Cancer: A Network Meta-analysis.
    Dong L; Zhu LN; Xie BJ; Li JB; Ding T; Jiang YF; Zhu ZN
    Pharmacotherapy; 2019 Dec; 39(12):1126-1136. PubMed ID: 31692005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of toxicities associated with the administration of taxanes.
    Markman M
    Expert Opin Drug Saf; 2003 Mar; 2(2):141-6. PubMed ID: 12904114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2
    Kuwayama T; Nakamura S; Hayashi N; Takano T; Tsugawa K; Sato T; Kitani A; Okuyama H; Yamauchi H
    Clin Breast Cancer; 2018 Dec; 18(6):474-480. PubMed ID: 30072191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials.
    Ginés J; Sabater E; Martorell C; Grau M; Monroy M; Casado MA
    Clin Transl Oncol; 2011 Jul; 13(7):485-98. PubMed ID: 21775276
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.